Generic Name: carfilzomib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Amgen

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Kyprolis is a proteasome inhibitor approved for relapsed or refractory multiple myeloma, used alone or in combination with other medications.

General Info

Kyprolis is a proteasome inhibitor that targets an enzyme that digests and eliminates excess proteins in myeloma cells. Blocking proteasome activity leads to myeloma cell death.

Clinical trials showed that Kyprolis, in combination with other medications, slows progression of multiple myeloma and prolongs survival.


Dosing Info:

Kyprolis is administered as an intravenous infusion on two consecutive weeks for three weeks, followed by a two-week rest period before starting another cycle.

Side Effects

Common side effects include fatigue, nausea, fever, shortness of breath,

diarrhea, headache, cough, swelling, insomnia and depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. It can cause birth defects and should not be used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: September 7, 2020